JP7058256B2 - 二環式ヘテロアリール置換化合物 - Google Patents

二環式ヘテロアリール置換化合物 Download PDF

Info

Publication number
JP7058256B2
JP7058256B2 JP2019501619A JP2019501619A JP7058256B2 JP 7058256 B2 JP7058256 B2 JP 7058256B2 JP 2019501619 A JP2019501619 A JP 2019501619A JP 2019501619 A JP2019501619 A JP 2019501619A JP 7058256 B2 JP7058256 B2 JP 7058256B2
Authority
JP
Japan
Prior art keywords
methylquinoxaline
thiazole
methoxy
oxy
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019501619A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019528247A5 (cg-RX-API-DMAC7.html
JP2019528247A (ja
Inventor
シャオジュン・ジャン
エルドン・スコット・プリーストリー
ジェイ・アレックス・ベイツ
オズ・スコット・ハルパーン
サミュエル・ケイ・レズニック
ジェレミー・エム・リヒター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019528247A publication Critical patent/JP2019528247A/ja
Publication of JP2019528247A5 publication Critical patent/JP2019528247A5/ja
Application granted granted Critical
Publication of JP7058256B2 publication Critical patent/JP7058256B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019501619A 2016-07-14 2017-07-13 二環式ヘテロアリール置換化合物 Active JP7058256B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662362113P 2016-07-14 2016-07-14
US62/362,113 2016-07-14
PCT/US2017/041878 WO2018013774A1 (en) 2016-07-14 2017-07-13 Bicyclic heteroaryl substituted compounds

Publications (3)

Publication Number Publication Date
JP2019528247A JP2019528247A (ja) 2019-10-10
JP2019528247A5 JP2019528247A5 (cg-RX-API-DMAC7.html) 2020-08-13
JP7058256B2 true JP7058256B2 (ja) 2022-04-21

Family

ID=59384258

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019501619A Active JP7058256B2 (ja) 2016-07-14 2017-07-13 二環式ヘテロアリール置換化合物

Country Status (7)

Country Link
US (2) US20190292176A1 (cg-RX-API-DMAC7.html)
EP (1) EP3484878B1 (cg-RX-API-DMAC7.html)
JP (1) JP7058256B2 (cg-RX-API-DMAC7.html)
KR (1) KR102460385B1 (cg-RX-API-DMAC7.html)
CN (1) CN109689647B (cg-RX-API-DMAC7.html)
ES (1) ES2823180T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018013774A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6903732B2 (ja) 2016-07-14 2021-07-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐａｒ４阻害剤としての三環式ヘテロアリール置換のキノリンおよびアザキノリン化合物
WO2018013772A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Monocyclic heteroaryl substituted compounds
KR102494647B1 (ko) 2016-07-14 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 비시클릭 헤테로아릴 치환된 화합물
CN109836360B (zh) * 2019-03-19 2021-08-13 南京恩泰医药科技有限公司 一种甲苯磺酸依度沙班中间体的制备方法及中间体化合物
CN113024475B (zh) * 2019-12-25 2022-08-09 宁夏大学 一种喹喔啉酮类化合物的合成方法
CN111440146B (zh) * 2020-05-15 2022-10-21 中国药科大学 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
JP7753950B2 (ja) * 2022-03-30 2025-10-15 三菱ケミカル株式会社 環状亜硫酸エステルの製造方法
WO2024023012A1 (en) 2022-07-28 2024-02-01 Bayer Aktiengesellschaft Process for preparation of 2-chloro-3-fluoro-4-alkoxy-anilines and 2-fluoro-3-chlorophenol
WO2024131948A1 (zh) * 2022-12-22 2024-06-27 人福医药集团股份公司 制备p2x3抑制剂的方法
CN115925588A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钠盐的制备方法
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025032129A1 (en) 2023-08-08 2025-02-13 Syngenta Crop Protection Ag Novel aminoindane and aminotetraline compounds
US11986461B1 (en) 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound
US11976055B1 (en) 2023-08-24 2024-05-07 King Faisal University 2-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-3-ol as an antitumor and antimicrobial compound
US11964959B1 (en) 2023-09-05 2024-04-23 King Faisal University 3-(4,5-Diphenyl-2-(pyridin-3-yl)-1H-imidazol-1-yl)-N,N-dimethylpopan-1-amine as an antimicrobial compound
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
US11952361B1 (en) 2023-12-26 2024-04-09 King Faisal University 2-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl) pyridin-3-ol as an antitumor and antimicrobial compound
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503756A (ja) 1996-11-06 2001-03-21 ダーウィン・ディスカバリー・リミテッド キノリン類およびこれらの治療的使用
WO2010035745A1 (ja) 2008-09-25 2010-04-01 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
JP2018515612A (ja) 2015-05-13 2018-06-14 セルビタ スプウカ アクツィーナ 置換キノキサリン誘導体

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1164459A (en) * 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
YU136287A (en) * 1986-07-25 1990-06-30 Boehringer Kg Process for preparing new 1,4 benzodiazepines
TW279162B (cg-RX-API-DMAC7.html) * 1991-09-26 1996-06-21 Mitsubishi Chem Corp
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6313126B1 (en) * 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
US6387942B2 (en) 2000-06-19 2002-05-14 Yung Shin Pharmaceutical Ind. Co. Ltd Method of treating disorders related to protease-activated receptors-induced cell activation
EP1348701A1 (en) 2002-03-28 2003-10-01 Warner-Lambert Company LLC (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
US20050272784A1 (en) 2004-05-07 2005-12-08 Xiaobing Li Inhibitors of bacterial Type III protein secretion systems
AU2005267798A1 (en) 2004-07-28 2006-02-09 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
KR20070098914A (ko) 2005-01-14 2007-10-05 제네랩스 테크놀로지스, 인코포레이티드 바이러스 감염을 치료하기 위한 인돌 유도체
WO2007149395A2 (en) 2006-06-20 2007-12-27 Amphora Discovery Corporation 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer
CN101479249B (zh) 2006-06-29 2012-10-10 霍夫曼-拉罗奇有限公司 苯并咪唑衍生物、其制备方法、它们作为fxr激动剂的用途及含有它们的药物制剂
WO2008073451A2 (en) 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
AU2008331480A1 (en) 2007-11-30 2009-06-11 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
ES2586459T3 (es) 2008-05-01 2016-10-14 Glaxosmithkline Llc Quinolinas y análogos relacionados como moduladores de sirtuina
EA021421B1 (ru) 2008-05-23 2015-06-30 Новартис Аг Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы, способ их получения, содержащая их фармацевтическая композиция и способ лечения заболеваний с применением таких соединений
JP5631310B2 (ja) 2008-07-23 2014-11-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 三環式ピラゾロピリジンキナーゼ阻害剤
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
WO2013130660A1 (en) 2012-02-28 2013-09-06 Amgen Inc. Amides as pim inhibitors
WO2013163244A1 (en) 2012-04-26 2013-10-31 Bristol-Myers Squibb Company Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
RS59882B1 (sr) 2012-04-26 2020-03-31 Bristol Myers Squibb Co Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za lečenje agregacije trombocita
AU2013251680A1 (en) 2012-04-26 2014-11-13 Bristol-Myers Squibb Company Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
US9617279B1 (en) 2014-06-24 2017-04-11 Bristol-Myers Squibb Company Imidazooxadiazole compounds
US9598419B1 (en) 2014-06-24 2017-03-21 Universite De Montreal Imidazotriazine and imidazodiazine compounds
WO2016138199A1 (en) 2015-02-26 2016-09-01 Bristol-Myers Squibb Company Benzothiazole and benzothiophne compounds
ES2929208T3 (es) 2015-02-26 2022-11-25 Univ Montreal Compuestos de imidazotiadiazol como inhibidores de PAR4
WO2017019828A1 (en) 2015-07-30 2017-02-02 Bristol-Myers Squibb Company Aryl substituted bicyclic heteroaryl compounds
JP6903732B2 (ja) 2016-07-14 2021-07-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｐａｒ４阻害剤としての三環式ヘテロアリール置換のキノリンおよびアザキノリン化合物
WO2018013772A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Monocyclic heteroaryl substituted compounds
KR102494647B1 (ko) 2016-07-14 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 비시클릭 헤테로아릴 치환된 화합물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503756A (ja) 1996-11-06 2001-03-21 ダーウィン・ディスカバリー・リミテッド キノリン類およびこれらの治療的使用
WO2010035745A1 (ja) 2008-09-25 2010-04-01 杏林製薬株式会社 ヘテロ環ビアリール誘導体及びそれらを有効成分とするｐｄｅ阻害剤
JP2018515612A (ja) 2015-05-13 2018-06-14 セルビタ スプウカ アクツィーナ 置換キノキサリン誘導体

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
REGISTRY（STN）[online]，2004.05.16[検索日 2021.06.09]CAS登録番号 682323-73-5
REGISTRY（STN）[online]，2004.05.27[検索日 2021.06.09]CAS登録番号 686704-00-7
REGISTRY（STN）[online]，2004.06.18[検索日 2021.06.09]CAS登録番号 695808-84-5
REGISTRY（STN）[online]，2004.08.27[検索日 2021.06.09]CAS登録番号 733696-13-4
REGISTRY（STN）[online]，2004.09.26[検索日 2021.06.09]CAS登録番号 752156-37-9
REGISTRY（STN）[online]，2004.10.03[検索日 2021.06.09]CAS登録番号 756430-39-4
REGISTRY（STN）[online]，2004.10.12[検索日 2021.06.09]CAS登録番号 761354-84-1
REGISTRY（STN）[online]，2004.10.29[検索日 2021.06.09]CAS登録番号 772293-06-8
REGISTRY（STN）[online]，2004.11.08[検索日 2021.06.09]CAS登録番号 776248-43-2
REGISTRY（STN）[online]，2004.11.08[検索日 2021.06.09]CAS登録番号 777011-48-0

Also Published As

Publication number Publication date
US20210163465A1 (en) 2021-06-03
US12060347B2 (en) 2024-08-13
JP2019528247A (ja) 2019-10-10
CN109689647A (zh) 2019-04-26
US20190292176A1 (en) 2019-09-26
EP3484878B1 (en) 2020-08-19
WO2018013774A1 (en) 2018-01-18
ES2823180T3 (es) 2021-05-06
KR20190027385A (ko) 2019-03-14
KR102460385B1 (ko) 2022-10-27
EP3484878A1 (en) 2019-05-22
CN109689647B (zh) 2023-01-20

Similar Documents

Publication Publication Date Title
JP7058256B2 (ja) 二環式ヘテロアリール置換化合物
TWI589569B (zh) 絲胺酸／酥胺酸激酶抑制劑
JP6389830B2 (ja) ベータ−セクレターゼ阻害剤としてのパーフルオロ化５，６−ジヒドロ−４ｈ−１，３−オキサジン−２−アミン化合物および使用方法
KR20220042431A (ko) 헤테로시클릭 rip1 키나제 억제제
EP3484881B1 (en) Bicyclic heteroaryl substituted compounds
JP6122877B2 (ja) ユビキチン活性化酵素のピラゾロピリミジニル阻害剤
WO2015059668A1 (en) Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
CA2851037A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
EP3555086B1 (en) 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use
JP2015508775A5 (cg-RX-API-DMAC7.html)
JP6903732B2 (ja) Ｐａｒ４阻害剤としての三環式ヘテロアリール置換のキノリンおよびアザキノリン化合物
TWI841134B (zh) 含二氮雜亞基磺醯結構的化合物及其在醫藥上的用途
WO2024230586A1 (zh) 含二氮杂亚基磺酰结构的化合物作为pkm2激动剂的新用途
WO2024245143A1 (zh) 含二氮杂亚基磺酰结构化合物的药物组合物在治疗贫血相关疾病中的用途
NZ623098B2 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200701

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200701

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220411

R150 Certificate of patent or registration of utility model

Ref document number: 7058256

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250